We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medical Solutn | LSE:MLS | London | Ordinary Share | GB0009739649 | ORD 2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.72 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSBS
RNS Number : 2567E
Source BioScience PLC
02 November 2015
2 November 2015
Source BioScience plc
(or "the Company")
Additional Listing on Exercise of Share Options
Source BioScience plc (LSE: SBS) announces that it has issued 124,564 new Ordinary Shares of 2 pence each in the Company ("New Ordinary Shares"), following net exercise of share options by employees under the Company's 2001 Approved Share Option Scheme.
Application has been made for the new Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange. Admission of the new Ordinary Shares will occur as soon as reasonably practical.
Following the issue and allotment, the Company's issued share capital will comprise 349,261,105 Ordinary Shares of 2 pence each. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure and Transparency Rules. The new Ordinary Shares will rank pari passu with existing Ordinary Shares.
Enquiries
Source BioScience plc
Dr Nick Ash, Company Secretary
Tel: +44 (0) 115 973 9010
Email: enquiries@sourcebioscience.com
www.sourcebioscience.com
About Source BioScience:
Source BioScience plc (LSE: SBS) is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating ten state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISELLFBEFFFFBX
(END) Dow Jones Newswires
November 02, 2015 10:17 ET (15:17 GMT)
1 Year Medical Solutions Chart |
1 Month Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
